candesartan/hydrochlorothiazide navamedic 8 mg / 12.5 mg tabletti
navamedic asa - hydrochlorothiazidum,candesartanum cilexetilum - tabletti - 8 mg / 12.5 mg - kandesartaani ja diureetit
candesartan/hydrochlorothiazide navamedic 16 mg / 12.5 mg tabletti
navamedic asa - hydrochlorothiazidum,candesartanum cilexetilum - tabletti - 16 mg / 12.5 mg - kandesartaani ja diureetit
sitagliptin/metformin glenmark 50 mg / 1000 mg tabletti, kalvopäällysteinen
glenmark arzneimittel gmbh - metformin hydrochloride, sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 50 mg / 1000 mg - metformiini ja sitagliptiini
sitagliptin/metformin glenmark 50 mg / 850 mg tabletti, kalvopäällysteinen
glenmark arzneimittel gmbh - metformin hydrochloride, sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 50 mg / 850 mg - metformiini ja sitagliptiini
candecam 8 mg / 5 mg tabletti
krka, d.d., novo mesto - amlodipine besylate, candesartan cilexetil - tabletti - 8 mg / 5 mg - kandesartaani ja amlodipiini
candecam 16 mg / 5 mg tabletti
krka, d.d., novo mesto - amlodipine besylate, candesartan cilexetil - tabletti - 16 mg / 5 mg - kandesartaani ja amlodipiini
candecam 16 mg / 10 mg tabletti
krka, d.d., novo mesto - amlodipine besylate, candesartan cilexetil - tabletti - 16 mg / 10 mg - kandesartaani ja amlodipiini
nanogam 50 mg/ml infuusioneste, liuos
prothya biosolutions netherlands b.v. - human normal immunoglobulin - infuusioneste, liuos - 50 mg/ml - ihmisen normaali immunoglobuliini intravaskulaariseen käyttöön
nanogam 100 mg/ml infuusioneste, liuos
prothya biosolutions netherlands b.v. - human normal immunoglobulin - infuusioneste, liuos - 100 mg/ml - ihmisen normaali immunoglobuliini intravaskulaariseen käyttöön
abiraterone mylan
mylan ireland limited - abirateroniasetaatti - prostatiset kasvaimet - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.